Completed NA INTERVENTIONAL NCT00618046

Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions

Sponsor: Roxane Laboratories

Conditions Epilepsy Seizures

Interventions Oxcarbazepine

Updated 6 times since 2017 Last updated: Jan 19, 2018 Started: Nov 30, 2004 Primary completion: Nov 30, 2004 Completion: Nov 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Epilepsy and Seizures, this trial is completed. The trial is conducted by Roxane Laboratories and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Feb 2018 — Jun 2018 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Feb 2018 [monthly]

Completed NA

First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Roxane Laboratories

Data source: West-Ward Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Springfield, United States